INGN Inogen (INGN) Insider Trading, Ownership & Congress Trades
Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0001294133
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
81
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $0 priced
What the filings say about INGN
Insiders, 180 days
-$142.5K net sold
1 seller · 0% of sales under a 10b5-1 plan
Inogen insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Inogen Inc insiders sold a net $142.5K of stock across 21 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 29, 2026.
- The trade is 217.1% of the 5,039 shares held after it.
- No other insider sold within 30 days.
- 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP Entrprs Enblmnt, Ch HR Off Yi Boyer Jennifer M sold about $72.1K of INGN on Jul 1, 2026, the largest insider sale at the company since 2024; 81 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 67.4% of the 15,977 shares held after it.
- No other insider sold within 30 days.
- 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP Entrprs Enblmnt, Ch HR Off Yi Boyer Jennifer M sold about $70.3K of INGN on May 29, 2026, the largest insider sale at the company since 2024; 81 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 6.3% of the 47,646 shares held after it.
- 1 other insider bought within 30 days.
- 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, CFO & Treasurer Bourque Michael J. bought about $25.0K of INGN on Mar 3, 2025, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 81 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 16.7% of the 70,274 shares held after it.
- 1 other insider bought within 30 days.
- 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President Smith Kevin Raymond Merrill bought about $100.2K of INGN on Mar 3, 2025, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 81 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Sep 1, 2022.
- The trade is 224.6% of the 4,452 shares held after it.
- No other insider sold within 30 days.
- 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Gen. Counsel & Secretary Somer Jason sold about $85.6K of INGN on May 10, 2024, the largest insider sale at the company since 2022; 81 funds added in the latest 13F quarter.21 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$142.5K over 180 days
more than 51% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
81 funds bought in last quarter
more than 58% of Medical Devices
Revenue
+5.9% year over year
below 61% of Medical Devices
Margin
-7.7% net margin
more than 59% of Medical Devices
Buybacks
$7.5M repurchased, FY to 2026-06-30
below 68% of Medical Devices
Short interest
6.4% of the float short (float per yahoo 2026-10-26) · 3.6 days to cover · settled 2026-09-30
more than 66% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch INGN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-20.9%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns INGN: institutional holders (13F)
13F holdings, latest reported quarter
1,748,986 sh
$11.3M
1,096,000 sh
$7.1M
1,038,316 sh
$6.7M
983,028 sh
$6.3M
937,334 sh
$6.0M
Congress trades in INGN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
INGN planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
JENNIFER YI BOYER
Filed 2026-07-01
$70.6K
INGN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Jacob Discovery Fund
$356.9K position · as of 2026-05-31
2.2%
Ultra-Small Company Fund
$1.0M position · as of 2026-06-30
1.0%
Invesco NASDAQ Future Gen 200 ETF
$81.7K position · as of 2026-05-31
0.4%
Cultivar ETF
$172.4K position · as of 2026-07-31
0.4%
Columbia Variable Portfolio - Small Cap Value Discovery Fund
$751.6K position · as of 2026-06-30
0.2%
Columbia Small Cap Value Discovery Fund
$4.2M position · as of 2026-07-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Scott Wilkinson
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2020
$2.5M
$484.8K
$870.8K
-35%
+33%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $142.5K sold by insiders over 180 days, 81 funds added last quarter. Each figure is a federal filing, dated the day it went public.
INGN financials
Revenue growth
+5.9%
XBRL, annual
Net margin
-7.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$354.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM INGN
| FY Dec 2025 | $348.7M |
| FY Dec 2024 | $335.7M |
| FY Dec 2023 | $315.7M |
| FY Dec 2022 | $377.2M |
| FY Dec 2021 | $358.0M |
| Jun 2026 | $95.1M |
| Mar 2026 | $85.1M |
| Dec 2025 | $81.7M |
| Sep 2025 | $92.4M |
| Jun 2025 | $92.3M |
| Mar 2025 | $82.3M |
| Dec 2024 | $80.1M |
| Sep 2024 | $88.8M |
At each fiscal year end
Single quarter
Net margin, TTM
+5.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM INGN
| FY Dec 2025 | +6.5% |
| FY Dec 2024 | +10.7% |
| FY Dec 2023 | +32.5% |
| FY Dec 2022 | +22.2% |
| FY Dec 2021 | +1.8% |
| Jun 2026 | -4.0% |
| Mar 2026 | -9.8% |
| Dec 2025 | +46.9% |
| Sep 2025 | -5.7% |
| Jun 2025 | -4.5% |
| Mar 2025 | -7.5% |
| Dec 2024 | +77.4% |
| Sep 2024 | -6.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$5.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM INGN
| FY Dec 2025 | -$13.7M |
| FY Dec 2024 | $2.6M |
| FY Dec 2023 | -$8.5M |
| FY Dec 2022 | -$40.9M |
| FY Dec 2021 | $18.2M |
| Jun 2026 | $2.2M |
| Mar 2026 | -$6.9M |
| Dec 2025 | -$1.9M |
| Sep 2025 | $1.6M |
| Jun 2025 | $3.7M |
| Mar 2025 | -$17.1M |
| Dec 2024 | -$3.3M |
| Sep 2024 | $5.3M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity INGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt INGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+11.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity INGN
| FY Dec 2025 | +12.4% |
| FY Dec 2024 | +19.0% |
| FY Dec 2023 | +40.8% |
| FY Dec 2022 | +25.1% |
| FY Dec 2021 | +1.8% |
| Jun 2026 | +11.2% |
| Mar 2026 | +10.8% |
| Dec 2025 | +12.4% |
| Sep 2025 | +24.3% |
| Jun 2025 | +23.6% |
| Mar 2025 | +22.7% |
| Dec 2024 | +19.0% |
| Sep 2024 | +73.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+7.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets INGN
| FY Dec 2025 | +7.6% |
| FY Dec 2024 | +11.5% |
| FY Dec 2023 | +28.0% |
| FY Dec 2022 | +18.7% |
| FY Dec 2021 | +1.3% |
| Jun 2026 | +7.0% |
| Mar 2026 | +6.9% |
| Dec 2025 | +7.6% |
| Sep 2025 | +15.1% |
| Jun 2025 | +14.7% |
| Mar 2025 | +14.2% |
| Dec 2024 | +11.5% |
| Sep 2024 | +46.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital INGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-13.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed INGN
| FY Dec 2025 | -13.3% |
| FY Dec 2024 | -18.0% |
| FY Dec 2023 | -36.9% |
| FY Dec 2022 | -22.2% |
| FY Dec 2021 | +2.2% |
| Jun 2026 | -13.4% |
| Mar 2026 | -13.6% |
| Dec 2025 | -13.3% |
| Sep 2025 | -13.6% |
| Jun 2025 | -13.7% |
| Mar 2025 | -14.0% |
| Dec 2024 | -18.0% |
| Sep 2024 | -23.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing INGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value INGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-2.7%
TTM free cash flow over market value at close 2026-10-26
FCF yield INGN
| FY Dec 2025 | -7.5% |
| FY Dec 2024 | +1.2% |
| FY Dec 2023 | -6.6% |
| FY Dec 2022 | -9.0% |
| FY Dec 2021 | +2.3% |
| Jun 2026 | -2.9% |
| Mar 2026 | -2.1% |
| Dec 2025 | -7.5% |
| Sep 2025 | -6.9% |
| Jun 2025 | -6.1% |
| Mar 2025 | -4.5% |
| Dec 2024 | +1.2% |
| Sep 2024 | +0.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing INGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $348.7M | $335.7M | $315.7M | $377.2M |
| Gross profit | $154.3M | $154.7M | $126.7M | $153.5M |
| Operating income | -$30.2M | -$42.5M | -$109.4M | -$85.2M |
| Net income | $22.7M | $35.9M | $102.4M | $83.8M |
| EPS (diluted) | -0.86 | -1.52 | -4.42 | -3.67 |
| Operating cash flow | -$11.2M | $5.9M | -$3.2M | -$37.5M |
| Cash | $103.7M | $113.8M | $125.5M | $187.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
INGN Stock Sonar score 5/7 axes
Find similar shapesCompareINGN ranks highest on profitability (71st percentile) and risk and compliance (70th), and lowest on growth (21st), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
INGN filings, in plain words
Are Inogen insiders buying or selling INGN?
In the 180 days to 2026-10-28, Inogen insiders were net sellers, a net $142.5K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Inogen insiders were net sellers of INGN, a net $142.5K across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
